Skip to main content

Advertisement

Table 1 Patients’ characteristics

From: Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate

Patient Sex Age (years) Weight (kg) Primary tumor Metastases Injected activity (MBq) Number of treatment cycles SPECT/CT acquisition times
C1 C2 C1 C2
1 M 75 74 Small intestine NET Nodes, mesentery, liver 7167 7073 4 NA 4 h, 24 h, 72 h, 192 h
2 M 59 72 Small intestine NET Nodes, liver, bone 7287 1 4 h, 24 h, 168 h
3 M 82 70 Small intestine NET Nodes, mesentery, bone 7180 6642 2 4 h, 24 h, 72 h 4 h, 24 h, 72 h, 192 h
4 M 71 71 Pancreas NET Liver 7054 7134 4 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 192 h
5 F 63 56 Pancreas NET Liver 7323 7071 4 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h
6 M 59 79 Small intestine NET Mesentery, liver 7207 7188 4 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h, 192 h
7 F 82 57 Pancreas NET Liver 7177 7239 4 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h, 192 h
8 M 61 74 Small intestine NET Nodes, mesentery, liver, bone 7298 7210 4 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h, 192 h
9 M 70 88 Small intestine NET Liver, bone 7222 7158 4 4 h, 24 h, 192 h 4 h, 24 h, 72 h, 192 h
10 M 78 89 Large intestine NET Nodes, liver 7162 6620 2 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 192 h
11 M 53 70 Small intestine NET Liver, bone 7102 7260 3 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h, 192 h
12 M 74 70 Small intestine NET Nodes, mesentery 7288 7578 3 4 h, 24 h, 72 h, 192 h 4 h, 24 h, 72 h, 192 h
  1. NA not available, C cycle, NET neuroendocrine tumor, † patient dead